Bruceoside A

Research use only, not for human use.

Bruceoside A could be transformed into the potent anticancer component brusatol in vivo, rather than its direct deglycosylated metabolite bruceosin.

Bruceoside A could be transformed into the potent anticancer component brusatol in vivo, rather than its direct deglycosylated metabolite bruceosin. It significantly inhibited P-388 lymphocytic leukemic cell RNA and protein synthesis in tissue culture.

——

Bruceoside A could be transformed into the potent anticancer component brusatol in vivo, rather than its direct deglycosylated metabolite bruceosin. Animal Model:Male ICR mice weighing 25.0 ± 5.0 g.Dosage:22.5 mg/kg.Administration:Intragastrically administrated.Result:Reached its highest levels in three hours with a half-life value of 3.99 h.

——

Others

Other Targets

——

——

——

63306-30-9

682.7

C32H42O16

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (366.21 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years